U.S. Insurance Stock News

For investors wondering if Cintas is still worth considering after its big run, or if most of the upside is already priced in, this article will walk through what the numbers are really telling us about the stock's value. The share price has climbed about 2.0% over the last week, 5.0% over the past month, and 5.0% year to date, on top of multi year gains of 74.1% over 3 years and 128.6% over 5 years that indicate the market already sees Cintas as a quality compounder. Recent coverage has...

Innoviva (INVA) just cleared a major hurdle with FDA approval for NUZOLVENCE, a first in class single dose oral antibiotic for uncomplicated gonorrhea, potentially reshaping both its pipeline value and long term growth story. See our latest analysis for Innoviva. The NUZOLVENCE approval lands at a time when Innoviva’s share price has climbed 13.62 percent year to date and 6.46 percent over 90 days, while its 3 year total shareholder return of 51.73 percent signals momentum that investors...

Wondering if WillScot Holdings is quietly turning into a value story after a rough stretch? This breakdown will help you figure out whether the current share price really reflects its long term potential. The stock has inched up about 1.9% over the last week and 10.0% over the past month, even though it is still down roughly 41.4% year to date and 41.6% over the last year. This hints that sentiment might be starting to shift. Recent coverage has focused on how WillScot is repositioning...

Nextracker recently reported that analysts expect quarterly EPS of US$0.93, lower than the prior-year period, alongside consensus revenue of US$808.49 million, which would mark strong year-on-year growth. Beyond these headline figures, investors are focusing on Nextracker’s expanded product scope, rising margins, and fully deleveraged, cash-rich balance sheet as key strengths. We’ll now examine how Nextracker’s expansion into higher-margin solutions and new regions could influence its...

Encompass Health (EHC) just posted third quarter revenue growth and unveiled its new Lake Worth rehabilitation hospital, a combination that underscores steady expansion as digital healthcare and aging demographics reshape post acute care demand. See our latest analysis for Encompass Health. Those expansion moves come after a strong run, with Encompass Health’s share price up a solid year to date and its three year total shareholder return of 86.59% signaling sustained momentum rather than a...

In December 2025, WeRide and Uber Technologies, in partnership with Dubai’s Roads and Transport Authority, officially launched public Robotaxi rides via the Uber app across Dubai’s Umm Suqeim and Jumeirah districts, initially with on-board specialists as a bridge to fully driverless commercial service expected in early 2026. This launch not only advances Dubai’s goal of making a quarter of all journeys autonomous by 2030, it also deepens Uber’s role as a partner-led autonomous mobility...

Tilray Brands (NasdaqGS:TLRY) just tied its next chapter to a big policy shift, with President Trump moving marijuana to Schedule III and the company launching Tilray Medical USA to pursue U.S. medical cannabis opportunities. See our latest analysis for Tilray Brands. That policy pivot has not stopped volatility, with a 7 day share price return of minus 21.2 percent and year to date share price return of minus 30.5 percent. The 3 year total shareholder return of minus 60.7 percent shows...

Himax Technologies announced that its subsidiary Liqxtal Technology, together with iCatch Technology, will showcase a joint AI-powered drone imaging solution at CES 2026, combining long-range electro-optical and thermal infrared cameras with an edge AI computing platform for applications such as aerial photography, security, and industrial inspection. This move highlights Himax’s push to extend its imaging and AI capabilities beyond automotive and consumer electronics into drone-based...

In recent days, Arbor Realty Trust has drawn heightened attention as multiple research firms lowered their recommendations, reflecting growing caution around its outlook and earnings estimates. This shift in analyst sentiment, combined with concerns highlighted by earnings forecast revisions, has sharpened the market’s focus on whether Arbor’s current valuation reflects its risks and potential. We’ll now examine how this recent wave of analyst downgrades could reshape Arbor Realty Trust’s...

If you are wondering whether Oracle is still a smart consideration at these levels, or if the easy gains are already behind it, you are in the right place to unpack what the current share price really implies. After climbing 10.7% over the last week and delivering a 155.1% return over three years, Oracle now trades around $197.49. This puts its 18.9% year-to-date gain and 16.4% 1-year return into sharper focus, despite a recent 1.4% dip over the past month. Investors have been reacting to...

Earlier this week, financial services firm Jefferies highlighted HubSpot as a key customer platform provider positioned for growth in 2026, arguing that market worries about Artificial Intelligence are already reflected in the valuation. The firm also pointed to AI-driven revenue acceleration and growing traction with larger customers as central to HubSpot's longer-term expansion potential and profitability outlook. We’ll now examine how Jefferies’ confidence in HubSpot’s AI-driven revenue...

W. P. Carey Inc. recently increased its quarterly cash dividend to $0.920 per share (US$3.68 annualized) and announced the upcoming departure of long-serving director Mark A. Alexander for health reasons, while also expanding its commercial real estate portfolio with the acquisition of a Life Time health club in Dublin, Ohio. Together, the dividend increase and ongoing property acquisitions highlight management’s current emphasis on sustaining shareholder income while continuing to grow...

General Mills (GIS) just delivered a quarter that cleared Wall Street’s bar, with management leaning on pricing tweaks and a refreshed product lineup to offset softer sales trends and heavier promotions. See our latest analysis for General Mills. Even with the latest earnings beat and an ongoing buyback program helping sentiment, the share price is still down sharply on a year to date basis. The weak three year and five year total shareholder returns suggest momentum has been fading rather...

SLB (SLB) just landed a five year contract with Aramco to deliver advanced stimulation, well intervention, frac automation, and digital solutions across Saudi Arabia’s unconventional gas fields, deepening its role in the Kingdom’s gas expansion plans. See our latest analysis for SLB. The Aramco win caps a busy stretch for SLB, coming shortly after its digital collaboration with Shell and an ESOP related share offering. It seems to be nudging sentiment back onside, even though the 1 year total...

Earlier in December, Freeport-McMoRan’s board declared a US$0.15 per-share cash dividend for payment in February 2026, while the company continued to manage a prolonged suspension at its Grasberg mine following a fatal incident and a series of related class action lawsuits over alleged safety and disclosure failures. At the same time, record-high copper prices and strong output from Morenci and Cerro Verde are helping support Freeport-McMoRan’s cash generation and its performance-based...

Many investors are asking whether Allstate at around $209 a share is still a smart buy or if most of the upside is already priced in. This article unpacks that question in detail. Despite a relatively flat 7 day move and a modest 1.6% dip over the last month, Allstate is still up 8.9% year to date and 118.6% over 5 years. This indicates that long term holders have been rewarded even if short term action looks quieter. Recently, the stock has been in focus as investors reassess large US...

Recent remarks from a senior research analyst have pushed Dave (DAVE) back into the spotlight, as its short term lending model and steady growth trends draw fresh attention from investors watching consumer finance. See our latest analysis for Dave. That upbeat commentary is landing just as momentum is heating up, with a 1 week share price return of 16.12 percent and a year to date share price gain of 164.96 percent. This reinforces a three year total shareholder return of 2555.73 percent that...

AerCap Holdings (NYSE:AER) has just delivered the first of ten Airbus A321neo jets to Thai Airways, kicking off a multiyear delivery stream through 2028 that reinforces AerCap’s role as a key lessor partner. See our latest analysis for AerCap Holdings. That steady operational progress is showing up in the market, with AerCap’s share price at $145.24 after a strong year to date and a robust one year total shareholder return that suggests momentum is still building rather than fading. If this...

Powell Industries (POWL) just delivered record profits and a fiscal 2025 earnings report that cleared Wall Street expectations by a wide margin. That upside surprise is reshaping how investors are valuing the stock. See our latest analysis for Powell Industries. The latest beat comes on top of a powerful run, with the share price at $336.17 after a year-to-date share price return of nearly 47 percent and a three-year total shareholder return above 900 percent, signalling momentum that...

Flex (FLEX) has quietly turned into one of the market’s steadier compounders, with the stock up roughly 64% this year and about 3x over the past 3 years. See our latest analysis for Flex. The stock’s 30 day share price return of 11.59 percent on a last close of 63.55 dollars builds on strong year to date momentum. Flex’s three year total shareholder return above 300 percent shows this has been a sustained, rerating story rather than a quick trade. Given that kind of run, it can be worth...

BioCryst Pharmaceuticals previously announced that the FDA approved its New Drug Application for an oral pellet formulation of once-daily ORLADEYO (berotralstat) as the first targeted oral prophylactic therapy for hereditary angioedema in children aged 2 to under 12 years in the U.S. This pediatric-friendly oral option addresses a long-standing gap where younger hereditary angioedema patients relied solely on intravenous or subcutaneous treatments, potentially easing daily treatment burden...

Republic Services (RSG) has been treading water lately, with the stock roughly flat over the past month and down about 6% in the past 3 months, despite steady earnings growth. See our latest analysis for Republic Services. Over the past year, Republic Services has quietly delivered a mid single digit total shareholder return while its 3 year and 5 year total shareholder returns of roughly 71% and 138% suggest longer term momentum remains firmly intact, even as near term share price returns...

Performance Food Group has announced a leadership succession in which long-time Chairman and CEO George Holm will step down as CEO to become Executive Chair, while current President and COO Scott McPherson will take over as CEO and join the board, with the transition effective January 1, 2026. This handover elevates an executive with deep experience across Performance Food Group’s core segments and prior CEO credentials, while keeping Holm closely involved in acquisitions and overall...

Galaxy Digital (GLXY) has had a choppy few months, with the stock up sharply year to date but giving back ground over the past 3 months, and that mix is exactly what makes it interesting now. See our latest analysis for Galaxy Digital. At today’s $24.43 share price, Galaxy’s strong year to date share price return contrasts with a weak 90 day stretch, while its multi year total shareholder returns still point to powerful long term momentum. If Galaxy’s move has you thinking about where capital...